NCT00084396View on ClinicalTrials.gov

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2007

Study Completion Date

September 30, 2016

Conditions

Breast Cancer

Interventions

DRUG

letrozole

PROCEDURE

conventional surgery

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT00084396 - Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer | Biotech Hunter | Biotech Hunter